Gufic BiosciencesBOM:509079 -2.09%73 EBITDA Margin % is 18.28% as of Mar. 2026, which is 10% above its 10-year median of 16.59. GuruFocus rates BOM:509079 with a GF Score™ of 73/100 and a GF Value™ of ₹407.00 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Gufic Biosciences ranks better than 59.56% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gufic Biosciences's EBITDA for the
three
months ended in Mar. 2026 was ₹460 Mil. Gufic Biosciences's Revenue for the
three
months ended in Mar. 2026 was ₹2,518 Mil. Therefore, Gufic Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was 18.28%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gufic Biosciences EBITDA Margin % Related Terms
Gufic Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gufic Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gufic Biosciences (BOM:509079) has a EBITDA Margin % of 18.28% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gufic Biosciences and its competitors. This is 10% above median its historical median of 16.59. Over the past decade, Gufic Biosciences' EBITDA Margin % has ranged from 10.11 to 21.01. According to the industry distribution chart, Gufic Biosciences ranks #385 out of 952 companies in the Drug Manufacturers industry, placing it in the top 40.4%.
Is Gufic Biosciences' EBITDA Margin % too high?
Gufic Biosciences' current EBITDA Margin % of 18.28% is 10% above median its 10-year median of 16.59. Over the past 10 years, this metric has ranged from a low of 10.11 to a high of 21.01. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Gufic Biosciences' value of 18.28% is 46.6% above this industry median. Based on the distribution chart, Gufic Biosciences ranks #385 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gufic Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #385 out of 952 companies for EBITDA Margin %. This puts Gufic Biosciences in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Gufic Biosciences' value of 18.28% is 46.6% above this benchmark. Historically, Gufic Biosciences' own EBITDA Margin % has ranged from 10.11 to 21.01 over the past decade. While the company's 10-year median is 16.59 vs. the industry median of 12.47, Gufic Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gufic Biosciences's current EBITDA Margin % of 18.28% is 46.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gufic Biosciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gufic Biosciences's current EBITDA Margin % is 18.28%, which is 10% above median its own 10-year median of 16.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹407.00, compared to a current price of ₹360.15 — trading 11.5% below its estimated fair value. The current EBITDA Margin % is 18.28%, which is 10% above median its 10-year median of 16.59 and 46.6% above the Drug Manufacturers industry median of 12.47. Gufic Biosciences' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current EBITDA Margin % is 18.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued.
The current stock price of ₹360.15 is trading 11.5% below its estimated GF Value™ of ₹407.00.
GuruFocus considers Gufic Biosciences to be Modestly Undervalued.
Key valuation signals for BOM:509079:
EBITDA Margin %: 18.28% (10% above median its 10-year median of 16.59)
GF Value™: ₹407.00 vs. price of ₹360.15 (11.5% below fair value)
Industry Position: 46.6% above the Drug Manufacturers median (#385 of 952)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
73GF Score
Get the complete analysis for BOM:509079
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
